|
注册号: Registration number: |
ChiCTR2400094884 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-30 14:14:44 |
|
注册时间: Date of Registration: |
2024-12-30 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
溃疡性结肠炎诊断标志物的筛选研究 |
|
Public title: |
Screening of diagnostic markers for ulcerative colitis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
溃疡性结肠炎诊断标志物的筛选研究 |
|
Scientific title: |
Screening of diagnostic markers for ulcerative colitis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘莹 |
研究负责人: |
刘莹 |
|
Applicant: |
Liu Ying |
Study leader: |
Liu Ying |
|
申请注册联系人电话: Applicant telephone: |
+86 13762247787 |
研究负责人电话:
Study leader's |
+86 731 52705221 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
40228498@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
40228498@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省湘潭市雨湖区大湖北路38号 |
研究负责人通讯地址: |
湖南省湘潭市雨湖区大湖北路38号 |
|
Applicant address: |
38 Dahu North Road Yuhu District Xiangtan City Hunan Province |
Study leader's address: |
38 Dahu North Road Yuhu District Xiangtan City Hunan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
湘潭市第二人民医院 |
||
|
Applicant's institution: |
Xiangtan Second People's Hospital |
||
|
研究负责人所在单位: |
湘潭市第二人民医院 |
||
|
Affiliation of the Leader: |
Xiangtan Second Peoples Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-xtkj-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
湘潭市第二人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Xiangtan Second People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-11-15 00:00:00 | ||
|
伦理委员会联系人: |
张娟 |
||
|
Contact Name of the ethic committee: |
Zhang Juan |
||
|
伦理委员会联系地址: |
湖南省湘潭市雨湖区大湖北路38号 |
||
|
Contact Address of the ethic committee: |
38 Dahu North Road Yuhu District Xiangtan City Hunan Provinc |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 731 52705150 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
914713416@qq.com |
|
研究实施负责(组长)单位: |
湘潭市第二人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xiangtan Second Peoples Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省湘潭市雨湖区大湖北路38号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
38 Dahu North Road Yuhu District Xiangtan City Hunan Provinc |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2024年湘潭市科技攻关与成果转换项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
2024 Xiangtan City Science and Technology Research and Achievement Transformation Project |
||||||||||||||||||||||
|
研究疾病: |
溃疡性结肠炎 |
||||||||||||||||||||||
|
Target disease: |
Ulcerative colitis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
溃疡性结肠炎(Ulcerative colitis,UC)是一种肠道非特异性慢性复发性疾病,其主要病变部位在大肠粘膜粘膜下层,好发于直肠或乙状结肠,可延伸造成全结肠溃疡,且存在癌变风险。UC发病率在北美和欧洲国家较高,但近年来在中国、日本等亚洲国家发病率呈逐步逐年上升趋势。目前UC诊断缺乏金标准,在排除感染性及其感染性结肠炎的基础上,需结合临床、消化道内窥镜下特点和组织病理学表现,进行综合判断,但这些多为侵入性检查方法,费用昂贵且操作复杂。利用粪便样本筛选溃疡性结肠炎诊断标志物,而粪便检测具有方便、无创、快速、廉价等优点,对于提高UC的诊断和鉴别诊断水平具有重要意义。 |
||||||||||||||||||||||
|
Objectives of Study: |
Ulcerative colitis (UC) is a non-specific chronic recurrent disease of the intestine. The main lesions are in the submucosa of the large intestine, usually in the rectum or sigmoid colon, which can extend to cause whole colon ulcers, and there is a risk of carcinogenesis. The incidence of UC is high in North America and European countries, but in recent years, the incidence rate in China, Japan and other Asian countries has gradually increased year by year. At present, there is no gold standard for the diagnosis of UC. On the basis of excluding infectious and infectious colitis, a comprehensive judgment should be made based on clinical, gastrointestinal endoscopic characteristics and histopathological findings. However, these are mostly invasive methods, expensive and complicated to operate. Fecal samples are used to screen diagnostic markers of ulcerative colitis, and fecal detection has the advantages of convenience, non-invasive, rapid and inexpensive, which is of great significance for improving the diagnosis and differential diagnosis of UC. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.既往有结肠癌、其他肠道肿瘤、结核性肠炎等病史的患者。 2.参与其他临床研究者。 孕妇及哺乳期妇女。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with a history of colon cancer, other intestinal tumors, and tuberculous enteritis. 2. Participate in other clinical investigators. Pregnant and breastfeeding women. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-01-01 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
一为病例记录,二为实验数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
One is the case record, and the other is the experimental data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |